🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Phase 3 Study in ET Patients

RecruitingPhase 3Ages 20 Years - anyAllPharmaEssentia Japan K.K.
NCT04655092 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

This is a Phase 3 open-label, multicenter, single arm study designed to evaluate the efficacy and safety and tolerability of P1101 patient with PV or ET in long-term.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patients who have completed the 52-week treatment duration in Study A19-201 and are considered by the investigator or sub investigator to be eligible for participation in this study * Patients who have given written informed consent to participate in this study Exclusion Criteria: * Patients who are considered by the investigator or sub investigator to be ineligible for continued treatment with P1101
💊

What it tests

  • P1101 (Ropeginterferon alfa-2b)
📍

Where

6 sites
Ehime University Hospital
Toon-shi, Japan
Mie University Hospital
Tsu, Japan
Osaka University Hospital
Suita-shi, Japan
Juntendo University Hospital
Bunkyo-ku, Japan
Tokyo Medical University Hospital
Shinjuku-ku, Japan
University of Yamanashi Hospital
Chuo-shi, Japan
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy